Trial reportBMC psychiatry2025
Long-term outcomes of assertive community treatment in Japan: 7-year follow-up of a randomized controlled trial.
Trial report in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Self- and observer-rated functioning and psychiatric readmission: findings from multicenter longitudinal data.Scientific reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWithin the context of community care, assertive community treatment (ACT) targeting individuals with severe mental disorders is typically a prolonged endeavor. Despite its extended nature, evidence on the long-term effects of ACT remains limited. This study aimed to assess the long-term effects of ACT services in Japan over 7 years by comparing readmission outcomes between the ACT and treatment-as-usual (TAU) groups.
methodsThis study traced participants from a prior randomized controlled trial (RCT) examining the short-term effects of ACT program in Japan. We assessed their readmission experiences, including the frequency and length (days) of readmissions over 7 years through medical record review. Multivariable analyses were conducted to examine outcomes by group.
resultsOf the 63 participants tracked for 7 years of follow-up (ACT group = 34, TAU group = 29), there were no significant group differences in readmission rate (TAU = 79% vs. ACT = 53%; odds ratio = 0.41, 95% CI = 0.12 to 1.35, p = 0.144) or cumulative days of hospitalization (Β = -75.66, 95% CI = -184.41 to 33.09, p = 0.173). However, the ACT group had significantly fewer hospitalizations (Β = - 1.03, 95% CI = - 1.97 to - 0.10, p = 0.030) than the TAU group. In particular, readmissions in the ACT group substantially decreased at 2 years after initial randomization.
conclusionIn the Japanese medical landscape, an ACT program for individuals with severe mental illness might help mitigate the frequency of readmission compared with TAU over the long term. In particular, the pronounced benefits of the ACT program appear to emerge approximately 2 years after the start of ACT services. Future research in different countries is needed to confirm the findings of this study, particularly the timing at which the long-term effects of ACT services emerge for various outcomes.
trial registrationThe trial was retrospectively registered on 5 August 2025 with the Japan Registry of Clinical Trials (Registration number: jRCT1030250281).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.